Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer

被引：0

作者：

Zhifei Li ^{[1
]}

Huan Zhao ^{[2
]}

Huihui Hu ^{[1
]}

Haili Shang ^{[1
]}

Yongjing Ren ^{[1
]}

Wenhui Qiu ^{[3
]}

Hao Su ^{[4
]}

Huifang Lyu ^{[5
]}

Xiaobing Chen ^{[1
]}

机构：

[1] Department of Oncology, the Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer Hospital, Henan Engineering Research Center of Precision Therapy of Gastrointestinal Cancer, Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Canc

[2] Henan University of Traditional Chinese Medicine

[3] State Key Laboratory of Esophageal Cancer Prevention&Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, School of Pharmaceutical Sciences,Zhengzhou University

[4] The First Affiliated Hospital of Xinxiang Medical University

[5] Department of Oncology, the Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer

来源：

Chinese Journal of Cancer Research | 2024年 / 36卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R735.2 [胃肿瘤];

学科分类号：

摘要：

Gastric cancer is one of the most prevalent cancers worldwide, and human epidermal growth factor receptor 2(HER2)-positive cases account for approximately 20% of the total cases. Currently, trastuzumab + chemotherapy is the recommended first-line treatment for patients with HER2-positive advanced gastric cancer, and the combination has exhibited definite efficacy in HER2-targeted therapy. However, the emergence of drug resistance during treatment considerably reduces its effectiveness; thus, it is imperative to investigate the potential mechanisms underlying resistance. In the present review article, we comprehensively introduce multiple mechanisms underlying resistance to trastuzumab in HER2-positive gastric cancer cases, aiming to provide insights for rectifying issues associated with resistance to trastuzumab and devising subsequent treatment strategies.

引用

页码：306 / 321

页数：16

共 50 条

[21] PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
Kim, Chan
Lee, Choong-Kun
Chon, Hong Jae
Kim, Joo Hoon
Park, Hyung Soon
Heo, Su Jin
Kim, Hyun Jeong
Kim, Tae Soo
Kwon, Woo Sun
Chung, Hyun Cheol
Rha, Sun Young
ONCOTARGET, 2017, 8 (69) : 113494 - 113501
[22] Trastuzumab-based treatment of HER2-positive metastatic gastric cancer
Dogan, I.
Karabulut, S.
Tastekin, D.
Paksoy, N.
Sakar, B.
Vatansever, S.
ANNALS OF ONCOLOGY, 2020, 31 : S205 - S205
[23] The efficacy and safety of trastuzumab for unresectable advanced HER2-positive gastric cancer
Matsueda, Katsunori
Toyokawa, Tatsuya
Horii, Joichiro
Fujita, Isao
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 95 - 95
[24] Trastuzumab deruxtecan in previously treated advanced HER2-positive gastric cancer
Pamuk, Aylin
Kuetting, Fabian
Alakus, Hakan
Bruns, Christiane
ONKOLOGE, 2021, 27 (01): : 74 - 76
[25] Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
Hunter, Francis W.
Barker, Hilary R.
Lipert, Barbara
Rothe, Francoise
Gebhart, Geraldine
Piccart-Gebhart, Martine J.
Sotiriou, Christos
Jamieson, Stephen M. F.
BRITISH JOURNAL OF CANCER, 2020, 122 (05) : 603 - 612
[26] Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
Francis W. Hunter
Hilary R. Barker
Barbara Lipert
Françoise Rothé
Géraldine Gebhart
Martine J. Piccart-Gebhart
Christos Sotiriou
Stephen M. F. Jamieson
British Journal of Cancer, 2020, 122 : 603 - 612
[27] HER2-Positive Gastric Cancer
Demetriades, Haralabos
ANNALS OF SURGICAL ONCOLOGY, 2011, 18 : S190 - S191
[28] HER2-positive gastric cancer
Boku, Narikazu
GASTRIC CANCER, 2014, 17 (01) : 1 - 12
[29] HER2-Positive Gastric Cancer
Haralabos Demetriades
Annals of Surgical Oncology, 2011, 18 : 190 - 191
[30] HER2-positive gastric cancer
Narikazu Boku
Gastric Cancer, 2014, 17 : 1 - 12

← 1 2 3 4 5 →